Page 3 - Genevant Sciences News Today

Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year, multi-pathogen, option-based deal follows multiple successful prior collaborations between Gritstone and Genevant EMERYVILLE, Calif., VANCOUVER, British Columbia, and BASEL, Switzerland, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology compa...

Last week, Canada-based Acuitas Therapeutics, Inc. (Acuitas) filed a complaint in the District of New Jersey for declaratory judgment of non-infringement and invalidity against Arbutus Biopharma Corp...

AVROBIO (NASDAQ:AVRO – Get Free Report) and Gritstone bio (NASDAQ:GRTS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Profitability This table compares AVROBIO and Gritstone bio’s […]

Lobbying revenues at K Street’s top firms began to rebound from a slower start to 2023, as lawmakers set to work on a slew of must-pass bills.

Vaxart (NASDAQ:VXRT – Free Report) and Gritstone bio (NASDAQ:GRTS – Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Earnings and Valuation This table compares Vaxart and Gritstone bio’s […]

By Blake Brittain (Reuters) - Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability to the U.S. government for paten...

Moderna failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the US government for alleged patent infringement by Modernas COVID-19 vaccine.

Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability to the U.S. government for patent infringement allegations based on COVID-19 vaccines it provided for the... | April 26, 2023

Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024.

Last week, Arbutus Biopharma Corp. and Genevant Sciences GmbH (collectively, Arbutus) filed a complaint for patent infringement in the District of New Jersey against Pfizer, Inc. and BioNTech SE.